PharmExec Direct eNewsletter

PharmExec Direct:
Having trouble viewing this e-mail? Click here.

You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile

PharmExec Direct | From the editors of Pharmaceutical Executive

May 13, 2010 | ISSUE NUMBER 148 VOL 8

Strategy
Pfizer on the Move, Literally
Pfizer’s mid-town tower is on the market, but the company claims that it won’t come at the cost of hundreds of jobs. One thing’s for certain: Pfizer is not leaving the Big Apple.

Events
BIO Convention: Potemkin Pavilions and the Power of NICE
Last week’s annual meeting of BIO in Chicago once again proved illustrative in showcasing the high profile that governments now plays as the biotech sector’s chief advocate.

Marketing
Unbranded Pharma Sites Gain Traction
More and more consumers are visiting unbranded pharmaceutical Web sites for information and tools to manage their disease. Is pharma ready to shift from branded to unbranded?

Technology
A Crash Course in SaaS
Terms like SaaS and Cloud Computing are today’s buzzwords, but what, exactly, do they mean? And how do they affect your company’s operations?

R&D
Merck Shows Off Bevy of New Drugs
While Merck’s net profits might be a little low in the wake of the Schering-Plough merger, it’s pipeline—and future sales—are far from bleak.

New & Noteworthy
Q&A: Geno Germano
Pfizer's Specialty Product Business Unit leader discusses his vision for the drug giant's specialty business; now the largest in the industry.

// Silence Therapeutics promoted Jorg Kaufmann to VP of research. // Jeffrey Dayno joined Labopharm as chief medical officer. // Jazz Pharmaceuticals added Rick Winningham to its board of directors. // Cempra Pharmaceuticals named Mark Hahn EVP and CFO. // Optimer Pharmaceuticals hired Pedro Lightinger as president and CEO and put him on its board. // Thomas Pitler joined Chimerix as VP of business development. //ThermoGenesis named David Carter to its board. // N30 Pharma added Howard Furst to its board. // BioNanomatrix elected David Barker to its board. // WuXi PharmaTech appointed Hao Zhou CFO. // Christopher Perkin was made president and CEO of Algorithme Pharma. //

Advertisement:
The Health Care Reform Opportunity: Implications and Recommendations for Life Sciences
Is health care reform a tough pill to swallow for your business? Although reform is changing the landscape, it is rife with opportunity. A report from Capgemini Consulting examines the challenges and implications resulting from health care reform and offers recommendations on how capitalize on the shifts within the industry. Download here

May 20 21 CFR Part 11, Computer Systems Validation and the Requirements of the FDA
11:00 AM ET; 8:00 AM PT
Register Free at pharmexec.com/csv

May 26 Moving Beyond Document Management to Enterprise Content Compliance
11:00 AM ET; 8:00 AM PT
Register Free at pharmexec.com/moving

May 24–27 Contract Lifecycle Management– I-many Summit 2010 User Conference
Miami, FL

June 13–17, 2010 Drug Industry Association’s Annual Meeting
Washington DC

Jun 22–23 Disease Education and Bio/Pharmaceutical Product Promotion Using Social Media Tools
Alexandria, VA

Jun 28–29 Clinical R&D Compliance Forum
Philadelphia, PA

Jul 26–27 Bio/Pharmaceutical Summit: Optimize Market Research and to Drive Accurate Product Forecasts
Philadelphia, PA

Jul 29–30 5th Annual Congress on Clinical Supply Chain Management
Princeton, NJ

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

If you plan to enter emerging markets over the next 3 years, what will be your primary entry strategy?

Abbott Creates Stand-Alone Established Products Division

Bayer Receives Approval For Its New Oral Contraceptive

GSK Statement on FDA Advisory Committee meeting on Rotavirus vaccines

Follow Pharm Exec on Twitter

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.